Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an update.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has scheduled a board meeting for 25 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. The board will also consider the publication of these results and discuss whether to recommend a final dividend, a decision that could affect shareholder returns and signal management’s confidence in the company’s financial performance.
The announcement also reiterates the current composition of ImmuneOnco’s board, listing its executive, non-executive and independent non-executive directors. This disclosure underscores the company’s governance framework as it approaches a key financial reporting milestone that will be closely watched by investors and other stakeholders on the Hong Kong market.
The most recent analyst rating on (HK:1541) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in the People’s Republic of China and listed on the Hong Kong Stock Exchange. The company operates through a board structure that includes executive, non-executive and independent non-executive directors, reflecting standard governance practices for a Hong Kong-listed healthcare issuer.
Average Trading Volume: 1,513,639
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.11B
For detailed information about 1541 stock, go to TipRanks’ Stock Analysis page.